The University of Sydney Honors Marshall Edwards Inc. Chairman
May 18 2004 - 9:28AM
PR Newswire (US)
The University of Sydney Honors Marshall Edwards Inc. Chairman
WASHINGTON, May 18 /PRNewswire-FirstCall/ -- The Chairman of
Marshall Edwards, Inc., Graham Kelly BSc(Vet), BVSc, PhD, has been
appointed an Adjunct Professor of The University of Sydney. The
University of Sydney is the oldest and one of the most prestigious
tertiary institutions in Australia, and over the past 150 years has
built an international reputation. It is Australia's leading
research-intensive university. Professor Kelly has been honored for
his continuing contribution to research by his alma mater the
Faculty of Veterinary Science. Marshall Edwards, Inc.
(NASDAQ:MSHL), is engaged in clinical trials of the investigational
anti-cancer drug phenoxodiol, and has the license to develop and
commercialize phenoxodiol and certain other anti-cancer compounds
from Novogen Limited. Professor Kelly founded Novogen Limited
(NASDAQ:NVGN) which first listed in 1994. Much of the early
research work underpinning the Group's intellectual property was
undertaken by Professor Kelly, who worked in the department of
experimental surgery, in the Faculty of Medicine, at the University
of Sydney, during the 1970s and 1980s. President and CEO of
Marshall Edwards, Inc., Christopher Naughton, said the Company was
delighted that the research contributions made by Professor Kelly
have been acknowledged, encouraged and supported by this
appointment. "Professor Kelly's appointment also strengthens the
ongoing scientific research and commercial collaboration that both
Novogen and Marshall Edwards have fostered with the University of
Sydney over recent years," Mr. Naughton said. Marshall Edwards Inc.
is 87% owned by Novogen Limited. More information on phenoxodiol
and on the Novogen group of companies can be found at
http://www.marshalledwardsinc.com/ and http://www.novogen.com/.
Phenoxodiol is an investigational drug and, as such, is not
marketed in the United States. Statements included in this press
release that are not historical in nature are "forward-looking
statements" within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. You should be
aware that our actual results could differ materially from those
contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of
risks and uncertainties, including, but not limited to, our failure
to successfully commercialize our product candidates; costs and
delays in the development and/or FDA approval, or the failure to
obtain such approval, of our product candidates; uncertainties in
clinical trial results; our inability to maintain or enter into,
and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements. DATASOURCE: Marshall Edwards,
Inc. CONTACT: Christopher Naughton of Marshall Edwards, Inc.,
Australia, +1-011-61-2-9878-0088, or David Sheon, +1-202-518-6384,
for Marshall Edwards, Inc., United States Web site:
http://www.marshalledwardsinc.com/ http://www.novogen.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024